1-169464882-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_006996.3(SLC19A2):c.*967A>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.235 in 152,490 control chromosomes in the GnomAD database, including 4,787 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.24 ( 4777 hom., cov: 32)
Exomes 𝑓: 0.20 ( 10 hom. )
Consequence
SLC19A2
NM_006996.3 3_prime_UTR
NM_006996.3 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.432
Genes affected
SLC19A2 (HGNC:10938): (solute carrier family 19 member 2) This gene encodes the thiamin transporter protein. Mutations in this gene cause thiamin-responsive megaloblastic anemia syndrome (TRMA), which is an autosomal recessive disorder characterized by diabetes mellitus, megaloblastic anemia and sensorineural deafness. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.69).
BP6
Variant 1-169464882-T-C is Benign according to our data. Variant chr1-169464882-T-C is described in ClinVar as [Benign]. Clinvar id is 293513.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.37 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC19A2 | NM_006996.3 | c.*967A>G | 3_prime_UTR_variant | 6/6 | ENST00000236137.10 | NP_008927.1 | ||
SLC19A2 | NM_001319667.1 | c.*967A>G | 3_prime_UTR_variant | 5/5 | NP_001306596.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC19A2 | ENST00000236137.10 | c.*967A>G | 3_prime_UTR_variant | 6/6 | 1 | NM_006996.3 | ENSP00000236137 | P1 | ||
SLC19A2 | ENST00000367804.4 | c.*967A>G | 3_prime_UTR_variant | 5/5 | 1 | ENSP00000356778 | ||||
SLC19A2 | ENST00000646596.1 | c.*967A>G | 3_prime_UTR_variant | 6/6 | ENSP00000494404 | |||||
SLC19A2 | ENST00000643377.1 | n.2183A>G | non_coding_transcript_exon_variant | 2/2 |
Frequencies
GnomAD3 genomes AF: 0.235 AC: 35658AN: 151942Hom.: 4762 Cov.: 32
GnomAD3 genomes
AF:
AC:
35658
AN:
151942
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.200 AC: 86AN: 430Hom.: 10 Cov.: 0 AF XY: 0.198 AC XY: 51AN XY: 258
GnomAD4 exome
AF:
AC:
86
AN:
430
Hom.:
Cov.:
0
AF XY:
AC XY:
51
AN XY:
258
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.235 AC: 35735AN: 152060Hom.: 4777 Cov.: 32 AF XY: 0.232 AC XY: 17280AN XY: 74336
GnomAD4 genome
AF:
AC:
35735
AN:
152060
Hom.:
Cov.:
32
AF XY:
AC XY:
17280
AN XY:
74336
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
690
AN:
3460
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Thiamine-responsive megaloblastic anemia Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at